Wish4Life Foundation, a US-based non-government organisation (NGO) dedicated to the care of children battling with cancer, is ...

Government funding will support 250 jobs in health-care technology at a Mississauga-based company. Hoffman-La Roche Limited’s ...

Wish4Life Foundation, a U.S.A based non-government organisation (NGO) dedicated to the care of children battling with cancer, ...

The immunohistochemistry test detects the folate receptor 1 protein, which is over-expressed in most ovarian cancers.

These jobs will propel the province towards being a global leader in biomanufacturing and life sciences. MISSISSAUGA, ON, Nov ...

AbbVie has announced the European Commission (EC) has granted marketing authorization for ELAHERE (mirvetuximab soravtansine) ...

at 07:35 Neuron23 Announces Usage of Roche's Digital Biomarker and Device in Parkinson's Disease Clinical Trial Neuron23® Inc., a clinical-stage biotechnology company focused on developing precision ...

Neuron23 unveiled details around its global Phase 2 NEULARK clinical trial of NEU-411 in people with early Parkinson’s disease.

Roche has secured CE mark approval for its immunohistochemistry (IHC) companion diagnostic test, VENTANA FOLR1 (FOLR1-2.1) ...

The Executive Vice-President, Diagnostics, Africa at Roche Diagnostics, Dr. Allan Pamba stated this in a statement to ...

The global cardiac biomarker diagnostic test kits market is poised for significant growth, with an estimated market size of ...

AbbVie receives European marketing approval for Elahere for the treatment of platinum-resistant ovarian cancer: North Chicago, Illinois Tuesday, November 19, 2024, 10:00 Hrs [IST] ...